Results 241 to 250 of about 1,553,534 (313)

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Lower urinary tract symptoms are beyond lower urinary tract

Gynecology and Minimally Invasive Therapy, 2015
Ming-Ping Wu
doaj   +1 more source

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

Clinical Pharmacology &Therapeutics, EarlyView.
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang, Logan Brooks, Denise M. Boudreau, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu   +6 more
wiley   +1 more source

ON TRICHOMONAS VAGINALIS INFESTATION IN THE MALE GENITO-URINARY TRACT

, 1952
Masao Nakano
openalex   +2 more sources

Primary urachal actinomycosis: A literature review

Asian Journal of Surgery, 2020
Jiaxuan Qin, Yuedong Chen, Jinchun Xing, Zonglong Cai   +3 more
doaj  

Interest of hair tests to discriminate a tail end of a doping regimen from a possible contamination in case of challenging an anti‐doping rule violation. V. Case reports involving trimetazidine, a drug where the concentration after a single 20 mg dose has been established

Drug Testing and Analysis, EarlyView.
From ingestion to hair incorporation Abstract The identification of trimetazidine, a medicine used for treating stable angina pectoris and for preventing angina attacks, has been recently observed in doping cases involving high profile athletes from various countries over the world.
Pascal Kintz, Alice Ameline, Laurie Gheddar   +2 more
wiley   +1 more source

THE EXPERIMENTAL STUDIES ON THE TRICHOMONAS VAGINALIS INFESTATION IN THE MALE GENITO-URINARY TRACT

, 1957
Masao Nakano
openalex   +2 more sources

Urinary tract infection by Trichomonas vaginalis in a newborn baby. [PDF]

, 1966
J M Littlewood, H Köhler
openalex   +1 more source

Lipid and Corticosteroid Biomarkers Under the Influence of Bisphosphonates

Drug Testing and Analysis, EarlyView.
The detection of bisphosphonates is important due to the potential integrity and welfare issues associated with use of these substances. Targeted detection of a nitrogenous and non‐nitrogenous bisphosphonate was detected for 8 h and 28 days post‐administration, respectively.
Kathy Tou, Adam Cawley, Glenys Noble, Jaymie Loy, David Bishop, John Keledjian, Kireesan Sornalingam, Stacey Richards, Shanlin Fu   +8 more
wiley   +1 more source